In a recent op-ed published in the Ottawa Business Journal, Dr. Jason Berman spoke about the importance of research innovation and cross-industry collaborations in tackling today’s healthcare crisis. “To improve healthcare meaningfully, we need the business community, the hospital community and the academic community to break down traditional silos and press fast-forward on promising innovations. The CHEO RI established a new Innovation Core, the purpose of which is to create a rich support ecosystem designed for healthcare innovators who aim to improve the lives of children and youth by actively working to expand the innovation core and its services at the CHEO RI.
This podcast will address how research and partnering with stakeholders across the spectrum- from high tech to business partners to patients could be an important aspect of reshaping tomorrow’s health care. Additionally, the importance of involving patients and families in research initiatives at the RI and how any type of reform needs to be informed by the patients and families involved will be discussed.
Speaker Name/Bio: Dr. Jason Berman is the CEO and Scientific Director of the CHEO Research Institute and the Vice-President Research at CHEO. He is also a Full Professor in the Department of Pediatrics at the University of Ottawa. Previously he served as Associate Chair, Research, Department of Pediatrics, and Professor of Pediatrics, Microbiology & Immunology and Pathology at Dalhousie University and interim Vice President Research, Innovation and Knowledge Translation for the IWK Health Centre in Halifax, Nova Scotia. He has overseen the pediatric leukemia program for the Maritimes since 2005 and chairs an international clinical trial for children with Down syndrome and myeloid leukemia. He is internationally recognized for pioneering research using zebrafish to study childhood cancers and rare inherited diseases. His laboratory has served as the Atlantic node of the Centre for Drug Research and Development and a national hub for zebrafish modeling of orphan diseases. He has been co-chair of the C17 Childhood Cancer Network Developmental Therapeutics Committee and Director of the Clinician Investigator Program and Medical Research Graduate Program at Dalhousie. He is president of the Canadian Society for Clinical Investigation, vice president of the Canadian Hematology Society and a founding member of the Canadian Rare Disease Models and Mechanisms Network.